Telehealth program for advance care planning in older adults with myeloid malignancies
A Telehealth Advance Care Planning Intervention for Older Patients With Myeloid Malignancies: A Pilot Randomized Controlled Trial
This study tests if a telehealth program that helps older adults with blood cancers talk about their serious illness and make healthcare plans can reduce their anxiety and improve communication with doctors.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 207 (estimated) |
| Ages | 60 Years and up |
| Sex | All |
| Sponsor | University of Rochester Academic / other |
| Locations | 1 site (Rochester, New York) |
| Trial ID | NCT05875805 on ClinicalTrials.gov |
What this trial studies
This project aims to evaluate the effectiveness of a telehealth-delivered Serious Illness Care Program designed to improve healthcare communication and reduce anxiety among older patients with myeloid malignancies. The program includes structured conversations between patients and healthcare providers, focusing on serious illness discussions and completion of advance directives. The study will compare the telehealth intervention to an education control group to assess its preliminary efficacy. Participants will include older adults diagnosed with conditions such as acute myeloid leukemia and myelodysplastic syndromes.
Who should consider this trial
Good fit: Ideal candidates are older adults aged 60 and above with a diagnosis of acute myeloid leukemia, myelodysplastic syndromes, or similar myeloid malignancies.
Not a fit: Patients who are younger than 60 or do not have a diagnosis of myeloid malignancies may not benefit from this study.
Why it matters
Potential benefit: If successful, this program could enhance communication about serious illness and improve patients' emotional well-being while ensuring their healthcare preferences are documented.
How similar studies have performed: Previous studies have shown success with similar telehealth interventions for serious illness conversations, indicating potential for positive outcomes in this population.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion and Exclusion Criteria for Patients Inclusion criteria: * Age ≥60 years * A diagnosis of AML, MDS, and similar myeloid malignancies (including but not limited to MDS/MPN overlap syndrome, myelofibrosis) * Being managed in the outpatient settings * Able to provide informed consent * English-speaking Exclusion criteria: \- None Inclusion and Exclusion Criteria for Caregivers Inclusion criteria: * Age ≥18 years * Selected by patient when asked if there is a "family member, partner, friend, or caregiver with whom you discuss or who can be helpful in health-related matters" * Able to provide informed consent * English-speaking Exclusion criteria: \- None Inclusion and Exclusion Criteria for Oncology Providers Inclusion criteria: \- Oncologists and/or APPs who will be conducting the telehealth-delivered ACP visit Exclusion criteria: \- None
Where this trial is running
Rochester, New York
- University of Rochester — Rochester, New York, United States (Recruiting)
Study contacts
- Principal investigator: Kah Poh Loh — University of Rochester
- Study coordinator: Kah Poh Loh, MD
- Email: Kahpoh_Loh@URMC.Rochester.edu
- Phone: 585-276-4353
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.